Survodutide Side Effects: Safety Signals and Warnings
Survodutide safety concerns are compound-specific. The main listed side effects are Nausea, Diarrhea, and Vomiting. The main warning signals are Investigational - not yet approved for any indication, GLP-1 class warning: potential risk of thyroid C-cell tumors, and Gastrointestinal side effects common during dose escalation.
Direct Answer
Survodutide now has Phase 3 topline obesity data, but its weight-loss signal sits below tirzepatide and retatrutide. Its best case remains differentiated liver and MASH biology: the glucagon receptor component may matter more for hepatic fat and MASH than for pure weight-loss ranking. Strong candidate, not the default obesity pick.
- Evidence grade
- Level B
- Research status
- Phase 3
- Category
- Weight Loss & Metabolic
- Best for
- Weight loss research, MASLD/NASH, GLP-1/glucagon dual agonism pharmacology
Reported Side Effects
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Decreased appetite
- Dyspepsia
- Injection site reactions
- Elevated heart rate
Warnings
- Investigational - not yet approved for any indication
- GLP-1 class warning: potential risk of thyroid C-cell tumors
- Gastrointestinal side effects common during dose escalation
- Glucagon component may transiently increase blood glucose - monitoring recommended in diabetic patients
- Not studied in patients with severe hepatic or renal impairment
Known or Plausible Interactions
- Insulin and sulfonylureas (increased hypoglycemia risk)
- Oral medications (delayed absorption from slowed gastric emptying)
- Glucagon (exogenous glucagon for hypoglycemia rescue may have altered response)
Regulatory Context
Investigational - not approved. Phase 3 trials are ongoing for obesity and MASH; SYNCHRONIZE-1 topline obesity results were announced in April 2026. Available through clinical trials only.
Evidence Snapshot
| Evidence grade | Level B |
|---|---|
| Research status | Phase 3 |
| Best supported outcomes | Body Weight Reduction (Level B), Liver Fat Reduction (Level B), Glycemic Control (Level B), and Gastrointestinal Adverse Events (Level B) |
| Primary citation count | 3 |
| Last reviewed | 2026-06-01 |
Related Guides
How to Cite This Page
ExaminePeptides. "Survodutide Side Effects: Safety Signals and Warnings." Last reviewed 2026-06-01. https://examinepeptides.com/answers/survodutide-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.